Home » Trials » SLCTR/2026/006


Effectiveness of the Co-developed Mobile Health (mHealth) Application versus Standard Antenatal Care in Reducing Pregnancy-related Anxiety in Sri Lanka: An Open-Label Randomized Controlled Trial

-

SLCTR Registration Number

SLCTR/2026/006


Date of Registration

03 Mar 2026

The date of last modification

Mar 03, 2026



Application Summary


Scientific Title of Trial

Effectiveness of the Co-developed Mobile Health (mHealth) Application versus Standard Antenatal Care in Reducing Pregnancy-related Anxiety in Sri Lanka: An Open-Label Randomized Controlled Trial


Public Title of Trial

Effectiveness of the Co-developed Mobile Health (mHealth) Application versus Standard Antenatal Care in Reducing Pregnancy-related Anxiety in Sri Lanka: An Open-Label Randomized Controlled Trial.


Disease or Health Condition(s) Studied

Pregnancy-related Anxiety


Scientific Acronym

None


Public Acronym

None


Brief title

None


Universal Trial Number

U1111-1333-1596


Any other number(s) assigned to the trial and issuing authority

EC-25-127, Ethics Review Committee, Faculty of Medicine, University of Colombo


Trial Details


What is the research question being addressed?

Can a co-developed mHealth application effectively reduce pregnancy-related anxiety compared to the standard antenatal care and improve the key obstetric outcomes among pregnant women at a tertiary hospital in Sri Lanka?


Type of study

Interventional


Study design

Allocation

Randomized controlled trial


Masking

Single blinded : Investigators, Data analysts, Healthcare providers, Outcome assessors


Control

Standard therapy/practice


Assignment

Parallel


Purpose

Supportive care


Study Phase

Not Applicable


Intervention(s) planned

Study Design: Open-label, randomized controlled trial (RCT) with parallel design and pre- and post-intervention outcome assessment. Individual participant level 1:1 random assignment will place participants in either the control group (standard prenatal care) or the intervention group (mHealth intervention). The SPIRIT 2025 statement guidelines regarding randomized trials were followed in the study design.

Study setting: Antenatal clinics at the Professorial unit of De Soysa Hospital for Women (DSHW) in Colombo.

Study population:
Pregnant women who attend the antenatal clinic at the Professorial unit of De Soysa Hospital for Women (DSHW) and meet the inclusion and exclusion criteria.

Intervention Arm: Co-developed Mobile Health (mHealth) Application:

Participants in the intervention group will receive access to a co-developed mobile health application designed to reduce pregnancy-related anxiety. The app was developed with input from pregnant women, midwives, obstetricians, psychologists, and IT specialists to ensure cultural relevance and usability in the Sri Lankan context.

Participants are expected to complete five psychoeducation modules (one-time completion), two visualization sessions per week (16 total over 8 weeks), and two breathing sessions per day (112 total over 8 weeks).The mHealth application includes the following intervention components:

  1. Psychoeducation Module: Psychoeducation consists of 5 modules as follows: Module 1: What is pregnancy-related anxiety? Module 2: Common anxieties during pregnancy Module 3: What to expect during pregnancy (Navigating physical and emotional changes during pregnancy) Module 4: Preparing for Birth and Postpartum Module 5: Managing Worry and Stress during Pregnancy. These are simple, evidence-based information about pregnancy-related anxiety, normal emotional changes, coping strategies, and when to seek help. All the psychoeducation modules are available in the application but are locked. Only the first module will be kept unlocked. Once participants complete the first module, they will provide a rating from 1-5 on the module's usefulness, after which the second module will be unlocked. The same process will be followed for the rest of the psychoeducation module. Participants will continue to have access to previously unlocked psychoeducation modules throughout the intervention period.

  2. Mindful Breathing Exercise: Guided breathing exercise to promote relaxation and reduce anxiety symptoms. An audio instruction and a visual of a breathing exercise are provided.

  3. Visualization Exercise: Short, calming visualizations to support emotional regulation and positive birth expectations. An audio instruction and a visual of a visualization exercise are provided.

In addition to the above three main interventions, we have the following two features.

Self-monitoring Tools: o Daily mood tracking o Reminder prompts

Practical Support Features: o Week-by-week pregnancy guide o FAQs on pregnancy concerns o Emergency contacts o Support contact details (e.g., trainee health psychologist)

Participants will be asked to use the app daily for a period of 8 weeks, in addition to continuing their routine antenatal care at their respective clinics or hospitals. Usage is self-paced, and participants can engage with any module at their convenience.

No medication or invasive procedures are involved. The intervention is purely psychological and behavioral, delivered through a mobile application. Usage of these intervention components is monitored via backend analytics, which involves the process of gathering, processing, and analyzing data on the server-side of the software application.

Participants are expected to complete at least two psychoeducation sessions each week, two visualization sessions each week, and two breathing sessions per day during the intervention period. If participants do not reach the above limit, they will not be excluded from the study. They will be followed up on and encouraged to reach the limit.

Participants in the intervention group will also receive usual antenatal care provided through their chosen routine government and/or private maternal health services.

Control Arm: Standard Antenatal Care

Participants in the control group will receive usual antenatal care provided through their chosen routine government and/or private maternal health services, without access to the mHealth application during the trial period.

Blinding will be achieved as follows:

The principal investigator, administrators, and data analysts will be blinded to minimize bias. Randomization and intervention administration will be conducted solely by the designated Research Assistant, who will also monitor participant activity completion through direct follow-up and backend checks supported by the software development team. Outcome assessments and statistical analyses will be performed by an independent statistician who will be blinded to group assignments throughout. Importantly, the principal investigator will not be involved in randomization, intervention delivery, monitoring, outcome assessment, or data analysis, ensuring complete separation from all processes that could introduce bias. Only the participants will not be blinded to the allocation.


Inclusion criteria

  1. Pregnant women with uncomplicated singleton pregnancies with a period of gestation between 12 and 28 weeks.
  2. Pregnant women who can read and comprehend Tamil or Sinhala (since the intervention is bilingual).
  3. Pregnant women who scored mild to moderate levels on the Pregnancy-related Anxiety Questionnaire Revised 2, translated and validated through the Delphi process, as well as an additional screening step by a consultant psychiatrist to exclude severe anxiety and depression.
  4. Pregnant women who have access to an Android or iOS smartphone or tablet with an internet connection

Exclusion criteria

  1. Pregnant women with a documented diagnosis of a major mental disorder, such as major depression, schizophrenia, bipolar disorder, obsessive-compulsive disorder, post-traumatic stress disorder, and personality disorders.
  2. Pregnant women who have previously enrolled in a similar digital mental health intervention.


Primary outcome(s)

1.

Change in mean scores of anxiety measured through the validated questionnaire (PRAQ-R2). The tool consists of 10 items, divided into three subscales/components. The 3 conponents incude: fear of giving birth, worries about bearing a handicapped child and concerns about own appearance. Participants will be recruited during the end of the first trimester and second trimester of pregnancy (approximately 12–28 weeks of gestation).

[

Assessed at baseline and at two weeks from the end of the intervention (Week 10).

]

Secondary outcome(s)

1.

Reduction in mean scores of breastfeeding efficacy assessed using the Breastfeeding Self-Efficacy Scale – short form (BSES-SF)

[

Assessed at 1 week and 4 weeks postpartum.

]
2.

Reduced neonatal intensive care unit (NICU)admissions assessed through hospital records.

[

Assessed after delivery

]
3.

Reduction in the proportion requiring extra pain relief measured by recording the type and frequency of analgesic methods used during labour (e.g., pethidine, epidural) from labor charts.

[

Assessed after delivery

]
4.

Reduction in mean scores of postnatal depressive symptoms assessed using the Edinburgh Postnatal Depression Scale (EPDS)

[

Assessed at 6 weeks postpartum

]
5.

Appropriateness, acceptability, and feasibility of the co-developed mHealth intervention as perceived by pregnant women in the intervention group assessed using the three purpose-developed tools: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM)

[

Assessed after the completion of the intervention

]

Target number/sample size

72 (36 in each arm)


Countries of recruitment

Sri Lanka


Anticipated start date

2026-03-03


Anticipated end date

2026-09-01


Date of first enrollment


Date of study completion


Recruitment status

Pending


Funding source

Investigator Funded


Regulatory approvals

Not applicable



State of Ethics Review Approval


Status

Approved


Date of Approval

2025-11-20


Approval number

EC-25-127


Details of Ethics Review Committee

Name: Ethics Review Committee, Faculty of Medicine, University of Colombo
Institutional Address:Faculty of Medicine University of Colombo P O Box 271, Kynsey Road, Colombo 8, Sri Lanka
Telephone:+94-11-2695300 ext 240 Fax: +94-11-2691581
Email: erc@med.cmb.ac.lk

Contact & Sponsor Information


Contact person for Scientific Queries/Principal Investigator

Ahamad Salman Amathullah
Principal Investigator
WV27+H99 Faculty of Graduate Studies, 35/30 Prof Stanley Wijesundera Mawatha, Colombo 00700
0112 055 656
0763712338

amathullahsalman99@gmail.com

Contact Person for Public Queries

Proffesor Mohamed Rishard
Professor, Department of Obstetrics and Gynaecology Faculty of Medicine, University of Colombo, Sri Lanka.
Department of Obstetrics and Gynaecology, Faculty of Medicine, No.25, Po Box. 271, Kynsey Road, Colombo – 08, Sri Lanka.
+94 112 695 300 ext:161
0773741850

mrishard@obg.cmb.ac.lk
https://www.res.cmb.ac.lk/medicine/mrm-rishard/


Primary study sponsor/organization

Faculty of Graduate Studies, University of Colombo.

WV27+H99 Faculty of Graduate Studies, 35/30 Prof Stanley Wijesundera Mawatha, Colombo 00700



https://fgs.cmb.ac.lk/

Secondary study sponsor (If any)







Trial Completion details


Do the investigators plan to share identified individual clinical trial participant-level data (IPD)?

Yes


IPD sharing plan description

The individual participants data will be made available after deidentification including text, table, figures, and appendices. The study protocol will be made available. Data will be shared at the end of 12 months after the completion of the study and ending 24 months following article publication. Access will be granted to researchers who submit a methodologically sound proposal, either to achieve the aims outlined in the approved proposal or for inclusion in individual participant data meta-analyses. Data access will be provided following a formal written request to the principal investigator, review and approval of the request, and signing of a data sharing agreement specifying conditions of use, confidentiality, and non-disclosure.


Study protocol available

No


Protocol version and date

Not Available


Protocol URL

Not Available


Results summary available

No


Date of posting results


Date of study completion


Final sample size


Date of first publication


Link to results


Brief summary of results